Insider Buying: Actuate Therapeutics, Inc. (NASDAQ:ACTU) Director Purchases 71,428 Shares of Stock

Actuate Therapeutics, Inc. (NASDAQ:ACTU) Director Leslie W. Kreis purchased 71,428 shares of the business’s stock in a transaction dated Friday, June 27th. The stock was bought at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the acquisition, the director owned 196,428 shares of the company’s stock, valued at approximately $1,374,996. The trade was a 57.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Actuate Therapeutics Stock Performance

Shares of Actuate Therapeutics stock opened at $6.74 on Thursday. The stock’s fifty day moving average price is $9.00 and its 200-day moving average price is $8.28. Actuate Therapeutics, Inc. has a 12 month low of $5.50 and a 12 month high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU) last issued its earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.06).

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ACTU. Craig Hallum began coverage on shares of Actuate Therapeutics in a report on Tuesday, April 22nd. They set a “buy” rating and a $21.00 price objective for the company. HC Wainwright increased their price objective on Actuate Therapeutics to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, June 3rd.

Hedge Funds Weigh In On Actuate Therapeutics

Institutional investors have recently bought and sold shares of the business. BIOS Capital Management LP bought a new stake in Actuate Therapeutics during the 4th quarter valued at $78,753,000. Voss Capital LP lifted its stake in shares of Actuate Therapeutics by 157.7% during the 1st quarter. Voss Capital LP now owns 142,381 shares of the company’s stock worth $964,000 after purchasing an additional 87,135 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Actuate Therapeutics during the fourth quarter valued at about $130,000. Sigma Planning Corp bought a new stake in Actuate Therapeutics during the fourth quarter valued at about $128,000. Finally, Goldman Sachs Group Inc. grew its stake in Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after purchasing an additional 11,105 shares during the last quarter.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.